IL295490A - omecamtiv mecarbil tablet - Google Patents
omecamtiv mecarbil tabletInfo
- Publication number
- IL295490A IL295490A IL295490A IL29549022A IL295490A IL 295490 A IL295490 A IL 295490A IL 295490 A IL295490 A IL 295490A IL 29549022 A IL29549022 A IL 29549022A IL 295490 A IL295490 A IL 295490A
- Authority
- IL
- Israel
- Prior art keywords
- tablet formulation
- omecamtiv mecarbil
- film coating
- tablet
- core
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062972506P | 2020-02-10 | 2020-02-10 | |
| PCT/US2021/017429 WO2021163172A1 (en) | 2020-02-10 | 2021-02-10 | Omecamtiv mecarbil tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL295490A true IL295490A (en) | 2022-10-01 |
Family
ID=74858801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295490A IL295490A (en) | 2020-02-10 | 2021-02-10 | omecamtiv mecarbil tablet |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230090391A1 (https=) |
| EP (1) | EP4103159A1 (https=) |
| JP (1) | JP7696353B2 (https=) |
| CN (1) | CN115279349A (https=) |
| AU (1) | AU2021221106A1 (https=) |
| BR (1) | BR112022015457A2 (https=) |
| CA (1) | CA3168513A1 (https=) |
| IL (1) | IL295490A (https=) |
| WO (1) | WO2021163172A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2522579T3 (es) | 2004-06-17 | 2014-11-17 | Cytokinetics, Inc. | Compuestos, composiciones y métodos |
| SG11201507258PA (en) | 2013-03-14 | 2015-10-29 | Amgen Inc | Heterocyclic compounds and their uses |
| DK3645002T3 (da) | 2017-06-30 | 2024-12-16 | Amgen Inc | Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer |
| AU2018294254C1 (en) | 2017-06-30 | 2022-10-13 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| PT3594199T (pt) | 2018-07-09 | 2020-09-04 | Amgen Inc | 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação |
| MA53226A (fr) | 2018-08-17 | 2021-11-24 | Amgen Inc | Sel et formes cristallines d'omecamtiv mecarbil |
| WO2020131574A1 (en) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| DK4243825T3 (da) | 2020-11-12 | 2025-12-01 | Amgen Inc | Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper |
| IL305751A (en) | 2021-03-10 | 2023-11-01 | Amgen Inc | SYNTHESIS OF OMECAMTIV MECARBIL |
| US20250161298A1 (en) * | 2022-02-22 | 2025-05-22 | Yale University | Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2419007T3 (es) * | 2005-12-15 | 2013-08-19 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y procedimientos |
| SG11201507258PA (en) * | 2013-03-14 | 2015-10-29 | Amgen Inc | Heterocyclic compounds and their uses |
| US9895308B2 (en) * | 2013-03-14 | 2018-02-20 | Amgen Inc. | Heterocyclic compounds and their uses |
| DK3645002T3 (da) * | 2017-06-30 | 2024-12-16 | Amgen Inc | Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer |
-
2021
- 2021-02-10 US US17/798,531 patent/US20230090391A1/en active Pending
- 2021-02-10 WO PCT/US2021/017429 patent/WO2021163172A1/en not_active Ceased
- 2021-02-10 CN CN202180013878.7A patent/CN115279349A/zh active Pending
- 2021-02-10 EP EP21710140.1A patent/EP4103159A1/en active Pending
- 2021-02-10 IL IL295490A patent/IL295490A/en unknown
- 2021-02-10 JP JP2022548433A patent/JP7696353B2/ja active Active
- 2021-02-10 BR BR112022015457A patent/BR112022015457A2/pt unknown
- 2021-02-10 AU AU2021221106A patent/AU2021221106A1/en active Pending
- 2021-02-10 CA CA3168513A patent/CA3168513A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4103159A1 (en) | 2022-12-21 |
| US20230090391A1 (en) | 2023-03-23 |
| JP2023513249A (ja) | 2023-03-30 |
| CN115279349A (zh) | 2022-11-01 |
| BR112022015457A2 (pt) | 2022-10-04 |
| AU2021221106A1 (en) | 2022-09-22 |
| JP7696353B2 (ja) | 2025-06-20 |
| WO2021163172A1 (en) | 2021-08-19 |
| CA3168513A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295490A (en) | omecamtiv mecarbil tablet | |
| JP4463875B2 (ja) | 医薬組成物 | |
| IL279035B2 (en) | Pharmaceutical combination, composition and combination composition containing a glucokinase activator and a K-ATP channel blocker, method for their preparation and use | |
| IL265777B2 (en) | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| JP2002524416A (ja) | 持続放出型ラノラジン製剤 | |
| IL171870A (en) | Modified-release tablet of bupropion hydrochloride | |
| JP2017501201A (ja) | Ａｚｄ９２９１を含む医薬組成物 | |
| NZ574200A (en) | Methods and medicaments for administration of ibuprofen and famotidine | |
| IL297776A (en) | Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib | |
| IL298525A (en) | Pralsetinib pharmaceutical compositions | |
| JPWO2009060952A1 (ja) | 新規製剤 | |
| IL280906B1 (en) | Spice formulations containing 3-(5,3-dimethyl-h1-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid | |
| NZ565591A (en) | Trazodone and cross linked high amylose starch composition for once a day administration | |
| US12161650B2 (en) | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof | |
| IL303789A (en) | A solid preparation for oral administration | |
| EP3796908B1 (en) | Controlled release propiverine formulations | |
| CN118986905B (zh) | 一种甲磺酸阿帕替尼片及其制备方法 | |
| EP4552633A1 (en) | Pharmaceutical compositions comprising amorphous solid solutions of rivaroxaban and copovidone and preparation methods thereof | |
| JP2024519917A (ja) | リアノジン受容体モジュレーターを含む医薬組成物およびそれらの使用 | |
| WO2024081554A2 (en) | Modified release tolcapone formulations | |
| JP2025512011A (ja) | デフェリプロンを含む修飾放出医薬製剤 | |
| US20120064161A1 (en) | Modified release niacin pharmaceutical formulations |